- Sepsis is the body’s over active and toxic response to an infection that causes hospitalization of more than 18 million people around the world every year, including 30,000 Canadians
- Declared a Global Health Priority by the World Health Organization in 2017
- 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment
September 13, 2018 – Vancouver, Canada: Noting World Sepsis Day, Sepset Biosciences Inc., a spin-out company of The Centre for Drug Research and Development (CDRD) in collaboration with Dr. Robert Hancock at The University of British Columbia, is raising awareness about sepsis: a serious medical condition that is the body’s overwhelming and life-threatening response to infection that can lead to tissue damage, organ failure, and death. It more common than heart attack and claims more lives than any cancer but is often misdiagnosed. It was declared a Global Health Priority by the World Health Organization in 2017.
As many as 80% of sepsis deaths in hospitals could be prevented with rapid diagnosis and treatment. Sepset Biosciences is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis. Sepset’s blood-based test works by detecting a unique biomarker signature based on the body’s immune response rather than the presence of a pathogen. Mortality from sepsis increases by 8% for every hour that treatment is delayed. Current methods to diagnose sepsis take more than 24 hours, by which time patients are often well on their way towards tissue damage, organ failure, and death.
“Sepsis is a global problem and we need a better and faster way of detecting sepsis to save hundreds of thousands of lives around the globe. After receiving promising results from an initial pilot study, we initiated a multi-country, observational prospective clinical study last year to validate and refine Sepset’s proprietary gene signature to quickly and accurately identify patients with sepsis,” said Prof. Bob Hancock, co-founder of Sepset. Dr. Olga Pena, coinventor of the technology and coordinator of the Sepset clinical study added, “We aim to complete review of the results in 2019. A successful study will allow us to define a commercial pathway for this much-needed diagnostic test.”
Sepsis causes the hospitalization of more than 18 million people around the world every year, including 30,000 Canadians, with a staggering 30% mortality rate while leaving most survivors suffering from long-term, physical and physiological effects. Many patients diagnosed with sepsis require care in the ICU, placing a considerable burden on the health care system. The total cost of treating sepsis in Canada amounts to $325 million annually. Despite the staggering number of Sepsis patients, and the devastating consequences caused by this illness, only 29% Canadians are aware of this condition.
– 30 –
About Sepset Biosciences Inc.: Sepset Biosciences Inc., a spin-off company by The Centre for Drug Research and Development (CDRD), in collaboration with Dr. Robert Hancock, UBC Killam Professor of Microbiology and Immunology and Director of the Centre for Microbial Diseases and Immunity Research at the University of British Columbia, is developing a first-in-class diagnostic assay for the early and rapid diagnosis of sepsis. www.sepset.ca
About The Centre for Drug Research and Development (CDRD): CDRD is Canada’s national drug development and commercialization centre working in partnership with academia, industry, government and foundations. CDRD provides the specialized expertise and infrastructure to identify, validate and advance promising discoveries, and transform them into commercially viable investment opportunities for the private sector — and ultimately into new therapies for patients. www.cdrd.ca
For additional information, please contact: Kamran Shaikh
PR Associates Cell: 778-846-5406